Cargando…
Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes
BACKGROUND: Excessive body fat may be a major cause of insulin resistance and diabetes. But body weight reduction by energy restriction may simultaneously reduce both fat and muscle. Skeletal muscle is an important organ for glucose metabolism regulation, and loss of muscle may deteriorate glucose m...
Autores principales: | Uchiyama, Syutaro, Sada, Yukiyoshi, Mihara, Syohei, Sasaki, Yosuke, Sone, Masakatsu, Tanaka, Yasushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416191/ https://www.ncbi.nlm.nih.gov/pubmed/37575352 http://dx.doi.org/10.14740/jocmr4987 |
Ejemplares similares
-
Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series
por: Ishii, Satoshi, et al.
Publicado: (2019) -
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance
por: Matsuba, Ren, et al.
Publicado: (2018) -
The effect of body fat mass and fat free mass on migraine headache
por: Jahromi, Soodeh Razeghi, et al.
Publicado: (2013) -
Body Fat Mass, Percent Body Fat, Fat-Free Mass, and Skeletal Muscle Mass Reference Curves for Czech Children Aged 6–11 Years
por: Zbořilová, Vendula, et al.
Publicado: (2021) -
Changes in predicted lean body mass, appendicular skeletal muscle mass, and body fat mass and cardiovascular disease
por: Kim, Seong Rae, et al.
Publicado: (2022)